Drug Discovery

Intellia Therapeutics and SparingVision enter strategic collaboration to develop ocular therapies

Intellia Therapeutics, and SparingVision have entered into a strategic collaboration to develop new genomic medicines making use of CRISPR/Cas9 technology to treat ocular diseases.

US FDA and EMA accept application for Novartis’ Beovu to treat DME

The US Food and Drug Administration (FDA) has approved biologics license application (sBLA) and the European Medicines Agency (EMA) has validated the type-II variation application for Novartis’ Beovu (brolucizumab) to treat patients with diabetic macular edema (DME).

Poseida, Takeda partner to develop eight in vivo gene therapy programmes

Poseida Therapeutics has signed a research collaboration and license agreement with Takeda Pharmaceutical Company to develop up to eight in vivo gene therapy programmes.

Pacira BioSciences to buy Flexion Therapeutics

Pacira BioSciences has signed a definitive agreement to acquire biopharmaceutical firm Flexion Therapeutics to strengthen its position in non-opioid pain management.

FDA accepts NDA for Acer and Relief’s urea cycle disorder therapy

The US Food and Drug Administration (FDA) has accepted the filing of a new drug application (NDA) for Acer Therapeutics and Relief Therapeutics’ ACER-001 (sodium phenylbutyrate) to treat people with urea cycle disorders (UCDs). 

AstraZeneca to acquire remaining stake in Caelum Biosciences

AstraZeneca’s subsidiary Alexion has announced plans to acquire all the remaining equity stake in Caelum Biosciences for up to $500m.

Appili, AiPharma partner to advance Avigan/Reeqonus global development

Appili Therapeutics has announced a strategic alliance with AiPharma to advance the global development of Avigan/Reeqonus (favipiravir).

UNION therapeutics, Innovent partner to develop and market orismilast in China

UNION therapeutics has signed a strategic collaboration and license agreement with Innovent Biologics for the development and commercialisation of orismilast in China.

Incyte and Syndax to jointly develop and commercialise axatilimab

Incyte has signed a collaboration and license agreement with Syndax Pharmaceuticals to develop and commercialise axatilimab for chronic graft-versus-host disease (cGVHD) and other fibrotic diseases.